{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:17:51Z","timestamp":1776784671457,"version":"3.51.2"},"reference-count":35,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2022.13336","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T11:41:40Z","timestamp":1652787700000},"source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of camrelizumab (a PD\u20111 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non\u2011small cell lung cancer"],"prefix":"10.3892","volume":"24","author":[{"given":"Xinlei","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Daqing Oil Field General Hospital, Daqing, Heilongjiang 163001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueliang","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Daqing Oil Field General Hospital, Daqing, Heilongjiang 163001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Daqing Oil Field General Hospital, Daqing, Heilongjiang 163001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"key20220630101125_b1-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20220630101125_b2-ol-24-01-13336","article-title":"Non Small Cell Lung Cancer","volume-title":"StatPearls","author":"Clark","year":"2021"},{"key":"key20220630101125_b3-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11864-019-0614-9","article-title":"Updates on minimally invasive surgery in non-small cell lung cancer","volume":"20","author":"Ikeda","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"key20220630101125_b4-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","article-title":"Update 2020: Management of non-small cell lung cancer","volume":"198","author":"Alexander","year":"2020","journal-title":"Lung"},{"key":"key20220630101125_b5-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"103144","DOI":"10.1016\/j.critrevonc.2020.103144","article-title":"Management guidelines for stage III non-small cell lung cancer","volume":"157","author":"Jazieh","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20220630101125_b6-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"519","DOI":"10.21037\/tlcr.2020.03.27","article-title":"Minimal invasive surgery in locally advanced N2 non-small cell lung cancer","volume":"10","author":"Patane","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"key20220630101125_b7-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"102862","DOI":"10.1016\/j.critrevonc.2019.102862","article-title":"Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines","volume":"148","author":"Passiglia","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20220630101125_b8-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.21037\/tlcr-21-259","article-title":"A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: Past, present and future","volume":"10","author":"Ren","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"key20220630101125_b9-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"300060519887275","DOI":"10.1177\/0300060519887275","article-title":"Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients","volume":"48","author":"Xiong","year":"2020","journal-title":"J Int Med Res"},{"key":"key20220630101125_b10-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jtho.2018.10.161","article-title":"Neoadjuvant crizotinib in resectable locally advanced non-small cell lung cancer with ALK rearrangement","volume":"14","author":"Zhang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"key20220630101125_b11-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1111\/1759-7714.14112","article-title":"Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: A case report","volume":"12","author":"Zhao","year":"2021","journal-title":"Thorac Cancer"},{"key":"key20220630101125_b12-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-019-01146-5","article-title":"Camrelizumab: First global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"key20220630101125_b13-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"key":"key20220630101125_b14-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"650394","DOI":"10.3389\/fonc.2021.650394","article-title":"Combination of sorafenib, camrelizumab, transcatheter arterial chemoembolization, and stereotactic body radiation therapy as a novel downstaging strategy in advanced hepatocellular carcinoma with portal vein tumor thrombus: A case series study","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol"},{"key":"key20220630101125_b15-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1158\/1078-0432.CCR-21-1698","article-title":"Camrelizumab plus famitinib in patients with advanced or metastatic renal cell carcinoma: Data from an open-label, multicenter phase II basket study","volume":"27","author":"Qu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20220630101125_b16-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): A randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"key20220630101125_b17-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lungcan.2021.08.006","article-title":"Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study","volume":"160","author":"Zhou","year":"2021","journal-title":"Lung Cancer"},{"key":"key20220630101125_b18-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"628124","DOI":"10.3389\/fonc.2021.628124","article-title":"Efficacy and safety of anti-pd-1 plus anlotinib in patients with advanced non-small-cell lung cancer after previous systemic treatment failure-a retrospective study","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"key20220630101125_b19-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jtho.2017.04.011","article-title":"The IASLC lung cancer staging project: External validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer","volume":"12","author":"Chansky","year":"2017","journal-title":"J Thorac Oncol"},{"key":"key20220630101125_b20-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1089\/jpm.2021.0599","article-title":"Eastern cooperative oncology group performance status #434","volume":"25","author":"Mischel","year":"2022","journal-title":"J Palliat Med"},{"key":"key20220630101125_b21-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20220630101125_b22-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J Thorac Oncol"},{"key":"key20220630101125_b23-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J Thorac Oncol"},{"key":"key20220630101125_b24-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: The common terminology criteria for adverse events version 4.0","volume":"67","author":"Chen","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"key20220630101125_b25-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: An open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20220630101125_b26-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","article-title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","volume":"30","author":"Aguilar","year":"2019","journal-title":"Ann Oncol"},{"key":"key20220630101125_b27-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.2147\/CMAR.S304820","article-title":"Lenvatinib plus camrelizumab versus lenvatinib monotherapy as post-progression treatment for advanced hepatocellular carcinoma: A short-term prognostic study","volume":"13","author":"Wei","year":"2021","journal-title":"Cancer Manag Res"},{"key":"key20220630101125_b28-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.21037\/atm-21-3352","article-title":"Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma","volume":"9","author":"Yang","year":"2021","journal-title":"Ann Transl Med"},{"key":"key20220630101125_b29-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.21037\/jtd-21-340","article-title":"Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma","volume":"13","author":"Wu","year":"2021","journal-title":"J Thorac Dis"},{"key":"key20220630101125_b30-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"653437","DOI":"10.3389\/fimmu.2021.653437","article-title":"Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: A cohort study and literature review","volume":"12","author":"Qiao","year":"2021","journal-title":"Front Immunol"},{"key":"key20220630101125_b31-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20220630101125_b32-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.athoracsur.2021.03.041","article-title":"Neoadjuvant PD-1 inhibitors and chemotherapy for locally advanced NSCLC: A retrospective study","volume":"113","author":"Chen","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"key20220630101125_b33-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"486","DOI":"10.21037\/atm-21-670","article-title":"The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer","volume":"9","author":"Wang","year":"2021","journal-title":"Ann Transl Med"},{"key":"key20220630101125_b34-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/17474124.2020.1807939","article-title":"The clinical application of camrelizumab on advanced hepatocellular carcinoma","volume":"14","author":"Chen","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"key20220630101125_b35-ol-24-01-13336","doi-asserted-by":"publisher","first-page":"700165","DOI":"10.3389\/fonc.2021.700165","article-title":"Could camrelizumab plus chemotherapy improve clinical outcomes in advanced malignancy? A systematic review and network meta-analysis","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T07:11:31Z","timestamp":1656573091000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2022.13336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,5,17]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2022.13336","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"article-number":"215"}}